TY - JOUR
T1 - Emerging immune targets for the treatment of multiple myeloma
AU - Sohail, Atif
AU - Mushtaq, Adeela
AU - Iftikhar, Ahmad
AU - Warraich, Zabih
AU - Kurtin, Sandra E.
AU - Tenneti, Pavan
AU - McBride, Ali
AU - Anwer, Faiz
N1 - Funding Information:
This work supported in part by grant P30 CA023074 from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Funding Information:
This work supported in part by grant P30 CA023074 from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Publisher Copyright:
© 2018 Future Medicine Ltd.
PY - 2018
Y1 - 2018
N2 - We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.
AB - We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.
KW - adoptive cell therapy
KW - antibodies
KW - antibody therapeutics
KW - chimeric antigen T cells
KW - immunotherapy
KW - multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=85041718852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041718852&partnerID=8YFLogxK
U2 - 10.2217/imt-2017-0136
DO - 10.2217/imt-2017-0136
M3 - Review article
C2 - 29421983
AN - SCOPUS:85041718852
VL - 10
SP - 265
EP - 282
JO - Immunotherapy
JF - Immunotherapy
SN - 1750-743X
IS - 4
ER -